What were BioNexus Gene Lab Corp's Q1 2026 revenue and EPS, and how do they compare year-over-year?

BioNexus Gene Lab Corp reported Q1 2026 revenue of $22.84K, representing a 98.9% year-over-year decrease; its net loss per share improved to ($0.23), a 35.2% improvement year-over-year.

What strategic shifts is BioNexus Gene Lab Corp undertaking in response to its financial performance?

The company is pivoting its business strategy toward CDMO services and the commercialization of VitaGuard™ MRD, following a major decline in Chemrex trading volume, and is exploring liquidity and treasury options—including digital-asset and ATM financing—to support future growth initiatives.

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)

May 15, 2026

BioNexus Gene Lab Corp reported Q1 2026 revenue of $22.84K, down 98.9% year-over-year, while reducing net loss per share to $0.23. The company plans to pivot toward CDMO services and VitaGuard MRD commercialization.

TradingView

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)